2 December 2013 | Geneva | On November 22, 2013, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicine Agency (EMA) has recommended the granting of a conditional marketing authorisation for delamanid, a new therapeutic agent, as part of an appropriate combination regimen for pulmonary multi-drug resistant tuberculosis (MDR-TB) in adult patients when an effective treatment regimen cannot otherwise be composed for reasons of resistance or tolerability. WHO aims to initiate a process of review of available data on the efficacy and safety of this compound, as well as on supplementary data being requested from independant experts. Based on that review, WHO will determine whether to develop interim guidance on the use of this medicine for the treatment of MDR-TB.
LONDON | 23 OCTOBER 2013 | Tuberculosis (TB) treatment has saved the lives of more than 22 million people, according to the WHO Global tuberculosis report 2013 published today. The new data confirm that the world is on track to meet the 2015 UN Millennium Development Goals (MDGs) target of reversing TB incidence, along with the target of a 50% reduction in the mortality rate by 2015 (compared to 1990). A special Countdown to 2015 supplement to this year’s report provides full information on the progress to the international TB targets. It details if the world and countries with a high burden of TB are “on-track” or “off-track” and what can be done rapidly to accelerate impact as the 2015 deadline approaches.
13 June 2013 | Geneva | For the first time in over 40 years, a new TB drug with a novel mechanism of action - bedaquiline- is available, and was granted accelerated approval by the United States Food and Drug Administration in December 2012.
There is considerable interest in the potential of this drug to treat MDR-TB. However, information about this new drug remains limited. It has only been through two Phase IIb trials for safety and efficacy. The World Health Organization (WHO) is therefore issuing “interim policy guidance”.
18 MARCH 2013 | GENEVA - WHO and the Global Fund to Fight AIDS, TB and Malaria said today that strains of tuberculosis with resistance to multiple drugs could spread widely and highlight an annual need of at least US$ 1.6 billion in international funding for treatment and prevention of the disease.
22 millionlives were saved through the Stop TB Strategy, 1995-2012.Fact sheet on tuberculosis
450 000people developed multidrug-resistant tuberculosis (MDR-TB) in the world in 2012.Q&A on MDR-TB
2 billionUS dollars per year needed to fill resource gap for implementing existing TB interventions.Information note on Global TB report 2013
- Tuberculosis fact sheet
- More fact sheets on TB
- 10 facts on tuberculosis
- What is TB? How is it treated?
- What is multidrug-resistant tuberculosis and how do we control it?
- Restoring hope in Swaziland: helping stop TB through earlier diagnosis
- Viet Nam: optimism for multidrug-resistant TB patients
- More feature stories